INSP — Inspire Medical Systems, Inc. stock price, charts and financials
QT84Inspire Medical Systems, Inc.Inspire Medical Systems, Inc. (NYSE: INSP) is a Healthcare company in the Medical - Devices industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
Latest market price
76.78
+4.04+5.55%
News
Up 5.6% — Hsbc Holdings PLC Has $274,000 Stock Holdings in Inspire Medical Systems, Inc. $INSP (defenseworld.net).
Medium confidence
TA
Loading chart...
Snapshot
| Index | - | P/E | 17.10 | EPS (ttm) | 4.49 | Insider Own | 2.39% | Shs Outstand | 28.91M | Perf Week | 5.18% |
| Market Cap | 2.22B | Forward P/E | 52.23 | EPS next Y | 1.47 | Insider Trans | -0.72% | Shs Float | 27.25M | Perf Month | 24.46% |
| Enterprise Value | 1.93B | PEG | 0.60 | EPS next Q | 0.11 | Inst Own | - | Short Float | 13.42% | Perf Quarter | 80.19% |
| Income | 131.00M | P/S | 2.42 | EPS this Y | -73.41% | Inst Trans | - | Short Ratio | 4.20 | Perf Half Y | 40.42% |
| Sales | 916.00M | P/B | 2.69 | EPS next Y | 23.15% | ROA | 14.58% | Short Interest | 3.66M | Perf YTD | -16.75% |
| Book/sh | 28.57 | P/C | 6.92 | EPS next 5Y | 28.31% | ROE | 17.62% | 52W High | 147.03 -47.78% | Perf Year | -4.02% |
| Cash/sh | 11.10 | P/FCF | 18.02 | EPS past 3/5Y | - | ROIC | 6.33% | 52W Low | 38.91 97.33% | Perf 3Y | -64.82% |
| Dividend Est. | - | EV/EBITDA | 24.10 | Sales past 3/5Y | 30.75% 51.31% | Gross Margin | 86.13% | Volatility | 5.25% 4.90% | Perf 5Y | -67.62% |
| Dividend TTM | - | EV/Sales | 2.10 | EPS Y/Y TTM | 156.57% | Oper. Margin | 6.02% | ATR (14) | 3.44 | Perf 10Y | - |
| Dividend Ex-Date | Jan 09, 2008 | Quick Ratio | 6.16 | Sales Y/Y TTM | 14.07% | Profit Margin | 15.03% | RSI (14) | 76.31 | Recom | 2.59 |
| Dividend Gr. 3/5Y | - | Current Ratio | 8.55 | EPS Q/Q | -68.89% | SMA20 | 16.10% | Beta | 0.69 | Target Price | 60.80 |
| Payout | 0.00% | Debt/Eq | 0.04 | Sales Q/Q | -7.37% | SMA50 | 29.54% | Rel Volume | 2.44 | Prev Close | 72.74 |
| Employees | 1,333 | LT Debt/Eq | 0.04 | Earnings | Nov 02 | SMA200 | 18.93% | Avg Volume | 870.62K | Price | 76.78 |
| IPO Date | May 03, 2018 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 159.34% 3.01% | Net Debt/EBITDA | -1.19 | Volume | 2,126,816 | Change | 5.55% |
Analyst Ratings
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Sep-11-26 | Reiterated | Stifel Nicolaus | Buy | $75 → $80 |
| Aug-04-26 | Reiterated | RBC Capital | Sector Perform | $45 → $60 |
| Aug-04-26 | Reiterated | Stifel Nicolaus | Buy | $65 → $75 |
| Aug-04-26 | Reiterated | Robert W. Baird | $54 → $59 | |
| Aug-04-26 | Reiterated | Piper Sandler | Neutral | $55 → $60 |
| Aug-04-26 | Reiterated | Evercore ISI Group | In Line | $40 → $54 |
| Aug-04-26 | Reiterated | Truist Securities | Hold | $54 → $62 |
| Aug-04-26 | Upgrade | Oppenheimer | Perform → Outperform | $175 → $85 |
| Jul-28-26 | Reiterated | UBS | Neutral | $67 → $39 |
| Jul-16-26 | Reiterated | Truist Securities | Hold | $50 → $54 |
Latest News· Times ET
Sep-16-26
Sep-16-2611:37PM
Sep-14-26
Sep-11-26
Sep-04-26
Sep-03-26
Sep-03-2611:31PM
Sep-02-26
Aug-26-26
Aug-26-2605:15AM
12:13AM
Aug-24-26
Aug-24-2611:55PM
Aug-23-26
Aug-23-2611:54PM
Aug-21-26
Aug-20-26
Aug-18-26
Aug-18-2611:45PM
03:06AM
Aug-09-26
Aug-09-2612:11AM
Company
Inspire Medical Systems, Inc. operates as a medical technology enterprise, concentrating on the development and commercialization of advanced, minimally intrusive therapies for patients diagnosed with obstructive sleep apnea (OSA) across both domestic U.S. and international markets. A cornerstone of its product portfolio is the Inspire system, an innovative neurostimulation solution that offers a safe and proven effective treatment for individuals experiencing moderate to severe forms of OSA. Additionally, the company is pioneering a novel, closed-loop technology designed to continuously track a patient's breathing patterns and administer mild stimulation to the hypoglossal nerve, thereby maintaining an open airway. Founded in 2007, Inspire Medical Systems maintains its corporate headquarters in Golden Valley, Minnesota.
Ownership
Per-holder 13F data hasn't been ingested for this ticker yet.
Financial Statements
DataTimeframe
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 916 | 912 | 803 | — | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 131 | 133 | 123 | — | — | — | — | — | — | |
| Gross Profit | 785 | 779 | 680 | — | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 633 | 625 | 530 | — | — | — | — | — | — | |
| Research and Development | 101 | 103 | 114 | — | — | — | — | — | — | |
| Other Operating Expense | 0 | 0 | 0 | — | — | — | — | — | — | |
| Operating Income | 52 | 51 | 36 | — | — | — | — | — | — | |
| Interest Expense | 0 | 0 | 0 | — | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 13 | 15 | 22 | — | — | — | — | — | — | |
| Net Income Before Taxes | 64 | 66 | 58 | — | — | — | — | — | — | |
| Income Taxes | -67 | -80 | 5 | — | — | — | — | — | — | |
| Consolidated Net Income | 131 | 145 | 54 | — | — | — | — | — | — | |
| Net Income From Continuing Operations | 131 | 145 | 54 | — | — | — | — | — | — | |
| Net Income | 131 | 145 | 54 | — | — | — | — | — | — | |
| EPS (Recurring) | 4.53 | 4.95 | 1.80 | — | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | 4.53 | 4.95 | 1.80 | — | — | — | — | — | — | |
| EPS (Diluted) | 4.49 | 4.89 | 1.75 | — | — | — | — | — | — | |
| EBITDA | 80 | 80 | 65 | — | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | 17.10 | 18.86 | 105.93 | — | — | — | — | — | — | |
| Price To Sales Ratio | 2.43 | 2.93 | 6.93 | — | — | — | — | — | — | |
| Gross Margin | 85.70 | 85.42 | 84.68 | — | — | — | — | — | — | |
| Operating Margin | 5.68 | 5.59 | 4.48 | — | — | — | — | — | — | |
| Net Margin | 14.30 | 15.90 | 6.72 | — | — | — | — | — | — | |
| Shares Outstanding | 29 | 29 | 30 | — | — | — | — | — | — | |
| Market Capitalization | 2,227 | 2,675 | 5,561 | — | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
Insider Trading
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Kelly Jason P | See Remarks | Aug 07 '26 | Sale | 59.55 | 963 | 57,347 | 18,985 | Aug 11 |
| Rondoni John | See Remarks | May 15 '26 | Sale | 43.28 | 2,641 | 114,302 | 27,165 | May 19 |
| Rondoni John | See Remarks | May 14 '26 | Sale | 43.01 | 700 | 30,107 | 29,806 | May 15 |
| mcCormick Shawn | Director | May 08 '26 | Sale | 45.31 | 696 | 31,536 | 27,712 | May 11 |
| Rondoni John | See Remarks | Jan 09 '26 | Sale | 100.00 | 109 | 10,900 | 13,797 | Jan 12 |
| mcCormick Shawn | Director | Dec 02 '25 | Sale | 139.00 | 1,200 | 166,800 | 24,846 | Dec 04 |
| mcCormick Shawn | Director | Nov 28 '25 | Sale | 127.48 | 2,000 | 254,960 | 26,046 | Dec 01 |
| Curet Myriam | Director | Aug 08 '25 | Sale | 77.28 | 4 | 309 | 3,365 | Nov 24 |
| Curet Myriam | Director | May 08 '25 | Sale | 153.22 | 2 | 306 | 3,369 | Nov 24 |
| Curet Myriam | Director | Apr 07 '25 | Buy | 148.26 | 1 | 148 | 3,371 | Nov 24 |
| Curet Myriam | Director | Mar 20 '25 | Buy | 163.84 | 4 | 655 | 3,370 | Nov 24 |
| Buchholz Richard | Chief Financial Officer | Aug 29 '25 | Sale | 93.39 | 11,000 | 1,027,290 | 44,867 | Sep 02 |
| Buchholz Richard | Chief Financial Officer | Aug 19 '25 | Option Exercise | 62.74 | 25,008 | 1,569,031 | 61,247 | Aug 21 |
| mcCormick Shawn | Director | Jun 04 '25 | Option Exercise | 16.00 | 4,000 | 64,000 | 28,046 | Jun 06 |
| Rondoni John | See Remarks | May 19 '25 | Sale | 149.38 | 1,734 | 259,025 | 13,766 | May 21 |
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.